– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory...
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia...
GE HealthCare’s Revolution Vibe CTi enables more facilities to elevate patient care by offering advanced cardiac imaging technology that helps...
DELRAY BEACH, Fla., March 28, 2025 /PRNewswire/ -- The global Analytical Standards Market, valued at US$1.44 billion in 2022, is forecasted...
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28,...
Call Scheduled for Monday, March 31, 2025 at 5:00 pm ETLITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics,...
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative...
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third...
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered...
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to...
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million...
Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of...
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium...
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as...
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2...
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) -...
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional...
FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to...
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- There exist numerous approaches to enhance muscle growth, a tantalizing prospect for...
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- A significant portion of the populace leads lifestyles that compromise both cognitive...